(Q35117254)

6 August 2017

title

Prevention of bone loss after withdrawal of tamoxifen (English)

1 reference

6 August 2017

1 reference

Adi Cohen

1

1 reference

6 August 2017

Jessica B Fleischer

2

1 reference

6 August 2017

Mariko K Johnson

3

1 reference

6 August 2017

Ijeoma N Brown

4

1 reference

6 August 2017

Andrew K Joe

5

1 reference

6 August 2017

Dawn L Hershman

6

1 reference

6 August 2017

Donald J McMahon

7

1 reference

6 August 2017

Shonni J Silverberg

8

1 reference

6 August 2017

publication date

1 March 2008

1 reference

6 August 2017

1 reference

6 August 2017

volume

14

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

162-167

1 reference

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

A high incidence of vertebral fracture in women with breast cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140137

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

27 September 2018

1 reference

12 December 2020

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

12 December 2020

Effects of tamoxifen on spinal bone density in women with breast cancer

1 reference

12 December 2020

Long-term sequelae from adjuvant chemotherapy

1 reference

12 December 2020

Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy

1 reference

12 December 2020

Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients

1 reference

12 December 2020

Bone loss induced by cancer treatment and its management

1 reference

12 December 2020

Evidence that Tamoxifen Preserves Bone Density in Late Postmenopausal Women with Breast Cancer

1 reference

12 December 2020

Identifiers

DOI

10.4158/EP.14.2.162

1 reference

6 August 2017

1 reference

6 August 2017

1 reference